HK Stock Market Move | GRAND PHARMA (00512) rose more than 6% in the morning. The new drug for myopia, GPN00884, has recently started phase IIa clinical trials in China.

GRAND PHARMA (00512) rose over 6% in the morning, reaching a 6.42% increase to HK$8.79 as of the report, with a trading volume of HK$101 million. On the news front, GRAND PHARMA recently announced that the global innovative ophthalmic drug GPN00884, used to slow the progression of myopia in children, has completed its first patient dosing in Phase IIa clinical trials in China. This means that GPN00884 will enter an important stage to explore drug dosage and evaluate preliminary efficacy. If the drug's effectiveness expectations are successfully met, a new treatment plan for slowing the progression of myopia in children may be introduced. It is worth noting that in July of this year, oxymetazoline hydrochloride nasal spray (OC-01) landed in mainland China, revolutionizing the treatment experience for dry eye patients in China through nasal spray. Recently, at the 11th Global Dry Eye Academic Conference, with the theme "Caring for Dry Eye Patients, Welcoming the Era of Native Tears - 2025 New Developments in Dry Eye Diagnosis and Treatment and the Construction of Ocular Surface Health Ecology," GRAND PHARMA successfully held a national launch event for OC-01, officially announcing the arrival of a new era in dry eye treatment from "external substitution" to "internal awakening" therapy.